Answers are grounded in this paper and cite their sources.
At a median of 10 years, prostate-cancer-specific mortality was low irrespective of the treatment assigned, with no significant difference among treatments. Surgery and radiotherapy were associated with lower incidences of disease progression and metastases than was active monitoring. (Funded by the National Institute for Health Research; ProtecT Current Controlled Trials number, ISRCTN20141297 ; ClinicalTrials.gov number, NCT02044172 .).
No takes yet. Share an insight, caveat, or question.
Hamdy et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: